清洁水平接受标准和HPLC-DAD方法验证用于测定Nabumetone残留物在制造设备上的应用

Nitin Dubey, Nidhi Dubey, Mayank Mandhanya, Dinesh Kumar Jain

**Department of Industrial Quality Assurance and Sophisticated Instrumentation, College of Pharmacy, IPS Academy, Indore 452012 (MP), India**

**Department of Pharmaceutical Analysis, School of Pharmacy, Devi Ahilya University, Indore 452011 (MP), India**

**Department of Pharmaceutics, College of Pharmacy, IPS Academy, Indore 452012 (MP), India**

**Received 20 December 2011; accepted 10 April 2012**

**Available online 25 April 2012**

**KEYWORDS**

Nabumetone; Residual estimation; Swab sampling; Cleaning validation; HPLC-DAD

**Abstract** Prevention of cross contamination with active pharmaceutical ingredients is crucial and requires special attention in pharmaceutical industries. Current method validation describes the determination of Nabumetone (NAB) residue on a stainless steel surface using swab sampling with a sensitive HPLC-DAD analysis. The acceptance limit was decided as 2 μg swab per 100 cm². Cotton swabs impregnated with extraction solution were used to determine residual drug content. Recoveries were 90.88%, 91.42%, and 92.21% with RSD ranging from 2.2% to 3.88% at three concentration levels. Residual concentration was found to be linear in the range of 0.1–4.56 μg/mL, when estimated using a Phenomenex Luna C₁₈ (25 cm × 5 μm × 4.6 mm i.d.) column at 1.0 mL/min flow rate and 230 nm. The mobile phase consisted of a mixture of methanol:acetonitrile:water (55:30:15, v/v/v). The LOD and LOQ for NAB were found to be 0.05 and 0.16 μg/mL, respectively.

The validated method was found to be simple, selective and sensitive for demonstration of cleaning validation of NAB residues on a stainless steel surface.

© 2012 Xi'an Jiaotong University. Production and hosting by Elsevier B.V.

**1. Introduction**

Cleaning validation is an important analytical challenge for pharmaceutical industries. It stems primarily as a part of mandatory good manufacturing procedure protocols due to the obvious cross contamination potential. Secondly, it requires development of selective and sensitive methods for quantitative estimation of residues over the surface of manufacturing equipment after cleaning procedure. It involves
identification of numerous sampling points in the manufac-
turing lane to demonstrate complete removal of residues. 
Current regulatory norms do not establish acceptance limits 
for residues, but let an analyst decide it on the basis of logical 
criteria such as risk associated with the quality or safety of 
finished product.

Generally the limit for maximum accepted residue of active 
ingredient (maximum allowable carryover, MACO) is based 
on mathematical formulae, therapeutic doses and toxicological 
profile, which is kept at a general limit of 10 µg/mL [1–4]. 
Several approaches to express acceptance limits have been 
proposed in the published scientific work. One approach is 
to compare visual limit of detection (VLOD) with pharmacology 
based criteria, where not more than 1/1000th of the therapeutic 

dose of active component should be carried over to the next 
batch as residue; lower of the two is considered as the residual 
acceptance criterion. Another approach involves estimating 
the total amount of allowable residue present on production 
line, which is termed as residual acceptance level (RAL). 
Further, the concentration of residue present per unit equipment 
surface area may be computed, which is termed as specific 
residual cleaning level (SRCL) or limit per surface area (LSA).

Nabumetone (NAB) is chemically 4-(6-methoxy-2-naphthalenyl)-2-butane; it is an ester prodrug of a new generation of effective and orally active angiotensin-II receptor antagonist (Fig. 1). It blocks the vasoconstrictor and aldosterone-secret-
ing effects of angiotensin-II, one of the most important 
regulators of blood pressure [5,6]. The determination of 
NAB from tablet formulation has been carried out by high performance liquid chromatography (HPLC), high performance thin layer chromatography (HPTLC) and spectro-
photometry, alone or in combination. Several analytical 
methods have been reported for their determination alone or 
in combination with other drugs in different dosage forms, 
biological fluids and urine using different analytical techniques 
[7–9]. Available literature revealed that no method related to 
residual determination of NAB was reported so far; hence it 
was found worthwhile to determine LSA of NAB and to carry 
out the development and validation of the method in order to 
ensure trace level estimation of residues and to demonstrate 
efficiency of the cleaning procedure.

2. Experimental

2.1. Reagent and chemicals

NAB reference standard (USP) was obtained from IPCA 
Labs, Ratlam, Madhya Pradesh, India, as a gratis sample. 
Niilitis (NAB, 500 mg) tablets were procured from the manufac-
turer. HPLC grade water was prepared by taking reverse osmosis water and passing it through a Milli-Q System 
(Millipore, Milford, USA). Alpha Swab polyester on a 
propylene handle-TX714A (ITW Tex wipe, USA) was used 
for extraction recovery sampling. HPLC grade acetonitrile and 
methanol were obtained from Merck, Germany. All other 
chemicals used were of analytical grade.

2.2. Chromatographic system and conditions

The LC system consisted of a (Shimadzu LC 10AT VP) 
gradient pump with a universal loop injector (Rheodyne 
7725i) of 20 µL injection capacity, a photodiode array detector 
(PDA), SPD-10 AVP and Phenomenex Luna C18 (25 cm × 5 
µm × 4.6 mm i.d.) column at 1.0 mL/min flow rate, using 
20 µL injection volume controlled by a PC work station 
equipped with the software CLASS-VP (software M-10, 
version 1.6; Shimadzu, Tokyo, Japan). Column temperature 
was ambient. The mobile phase consisted of a mixture of 
methanol:acetonitrile:water (55:30:15, v/v/v). The mobile 
phase solution was filtered through a 0.45 µm membrane filter 
(Millipore) and degassed prior to use. The extraction solution 
consisted of 60 mL mobile phase solution, 20 mL methanol 
and 20 mL water (50:20:30, v/v/v). All chromatographic 
experiments were performed in the isocratic mode. UV 
detection was performed at 230 nm. The method was validated 
as per ICH guidelines. The statistical analysis was performed 
using Microsoft Excel 2007.

2.3. Standard solution preparation

The stock solution of standard was prepared by accurately 
weighing NAB reference standard and transferring to a 50 mL 
volumetric flask. 20 mL of methanol was added and the 
content of flask was sonicated for 30 min. The solution was 
appropriately diluted with the mobile phase to get the final 
concentration of 0.020 mg/mL. A series of calibration stan-
dards were prepared by appropriately diluting standard NAB solutions to separate 100 mL volumetric flasks 
to get dilutions.

2.4. Sample solution preparation

10 cm × 10 cm of a stainless steel surface, appropriately 
cleaned and dried, was sprayed with 250 µL of standard stock 
solution for the positive swab control at all concentration 
levels, and the solvent was allowed to evaporate. The surface 
was wiped using a wet cotton swab, soaked with extraction 
solution (mobile phase:methanol:water; 60:20:20, v/v/v). The 
swab was squeezed into the swab tube as per the procedure 
mentioned in Section 2.5. The background control sample was 
prepared from the extraction solvent. The negative swab 
control was prepared similarly. Care was taken to avoid 
contact of swab with the test surface. Subsequently, the tubes 
were placed in an ultrasonic bath for 15 min and the solutions 
were analyzed by HPLC-DAD.

2.5. Swab wipes sampling protocol

Rinse and swab are two sampling methods available to 
demonstrate cleaning validation. The swab technique is a 
technique preferred by United States Food and Drug Admin-
istration [1,10,11]. The swabbing process is a subjective
manual process that involves physical interaction between the swab and the surface, and thus may vary from operator to operator [12–15]. So, a standardized motion protocol is required to establish reproducible recoveries. A patch of 4 x 4 in² swab was immersed in the extraction solution and folded diagonally. The excess solution was squeezed to avoid unnecessary dilution of the drug. The folded swab was kept between the thumb and second finger, so that necessary force may be applied over the surface through first finger. The surface was wiped horizontally, starting from outside towards the center. The fresh surface was exposed and repeatedly wiped to extract the maximum residue. Finally the swab was secured in a closed and labeled container for estimation.

3. Results and discussion

3.1. Acceptance limit calculation

Cleaning validation of production lane is one of the most critically controlled tasks. Visual as well as analytical observations help to achieve the goal. Considering SRCL, VLOD, MACO and stainless steel surface area of 10 cm x 10 cm, the calculated limit per surface area (LSA) was decided as 2 µg swab per 100 cm².

3.2. Optimization of chromatographic conditions

Best chromatographic conditions were achieved by optimizing the wavelength for detection, mobile phase composition and flow rate. The mobile phase consisted of a mixture of 55 mL methanol, 30 mL acetonitrile, and 15 mL water (55:30:15, v/v/v). Chromatographic conditions were optimized to achieve appropriate plate numbers, peak symmetry, resolution and tailing factor. The calibration curve showed good linearity for lower concentrations, required for trace level estimations at 230 nm.

3.3. Optimization of sample treatment

Cotton swabs were spiked with different quantities of drug and placed into tubes. The optimum conditions were achieved with mobile phase: methanol:water (60:20:20, v/v/v) as the extracting solvent and sonification time of 15 min.

3.4. Validation of the method

The main objective of this study was to develop an HPLC-DAD method for estimation of residues collected by swabs, without interference of impurities originating from the swabs, plates and extraction media. The method was validated for linearity, precision, limit of detection (LOD), limit of quantification (LOQ), accuracy, selectivity, and stability of analyte [15–17].

3.4.1. System suitability

The average number of theoretical plates per column was >3400, the USP tailing factor <1.2 and the resolution >2.0. Relative standard deviation (RSD) of the peak areas was <2.0%.

3.4.2. Specificity

The specificity of the method was checked by using standard, samples, the background control sample, the negative swab control, and a swabbed un-spiked stainless steel plate (Fig. 2), and four standard solutions were subjected to stress conditions, which involved storage under destructive conditions like elevated temperature (75 °C), acid environment, basic environment and oxidative condition (H₂O₂ for 24 h). Chromatographic resolution of more than 1.5 was achieved for NAB from unknown peaks.

3.4.3. Linearity

Standard solutions were analyzed at six different concentration levels ranging from 0.1 to 4.56 µg/mL, with six determinations at each level. Linearity was observed when mean response area was plotted against concentration, using the least square and regression method (Table 1).

| Statistical parameter | Values |
|-----------------------|--------|
| Concentration range (µg/mL) | 0.1–4.56 |
| Regression equation | y = 38782x + 33512 |
| Coefficient of determination | r² = 0.996 |
| Residual standard deviation | 9373.25 |

Table 1 Linear regression data in the analysis of NAB.

Figure 2 Chromatograms obtained from (A) a non-spiked stainless steel and (B) the excipient mixture.
3.4.4. LOD and LOQ
The LOD and LOQ were determined on the basis of standard deviation of the response (y-intercept) and the slope of the calibration curve at low concentration levels according to ICH guidelines [18–20]. The LOD and LOQ for NAB were found to be 0.05 and 0.16 μg/mL, respectively.

3.4.5. Precision and accuracy
Recovery is the percentage of residual material that is actually removed by the sampling technique. Concentration of the analyte was compared with that of the spiked sample at three different concentration levels, 6 replicates each (1.91, 3.18 and 4.56 μg/mL). Observations are reported (Table 2) as relative standard deviation (RSD) and the recovery (%). Observations demonstrate appropriateness of the method for the purpose of residue monitoring.

Six consecutive injections of standard solutions on two different days by different analysts and different reagents were performed to evaluate the inter-mediate precision of the method and expressed as the RSD. The RSD was found to be 2.24% and 3.88% for the first and second days, respectively. The observations indicate acceptable inter-mediate precision for NAB solution.

3.4.6. Robustness
Robustness of the HPLC-DAD method was demonstrated by evaluation of the effect of different chromatographic parameters on the resolution and the concentration of NAB samples (Table 3). The flow rate was varied from 0.5 mL/min to 1.5 mL/min. The concentration of methanol in the mobile was varied from 52% to 58% and response was recorded at 230±4 nm. Significant differences were not observed in chromatographic parameters.

3.4.7. Sample and standard stability
The stabilities of NAB in the swab matrix and NAB standard solution were tested by storing them at ambient temperature for 24 h. They were injected after 6 h, 12 h and 24 h against fresh standard solutions. The stabilities of the standard NAB solution (4.8 μg/mL) and sample solutions after 24 h showed 2.16% difference in results. The stability of NAB in swab matrix showed 2.87% difference in results. Chromatography of both the samples showed no additional peaks (Figs. 3 and 4).

3.4.8. Filter evaluation
Samples and standard solutions of NAB were filtered with Millipore millex—HV-PVDF 0.45 μm and millex—PTFE-0.45 μm, and compared with unfiltered samples. The Millipore millex—HV-PVDF 0.45 μm and millex—PTFE-0.45 μm pore size syringe filters were qualified for use with filter evaluation ratio 100.28% and 100.36% for NAB standard solution with PVDF and PTFE filters, respectively. For samples, the filter evaluation ratio was 100.28% and 101.13% for PVDF and PTFE filters, respectively.

### Table 2
| Conc. added (μg/mL) | Conc. found (μg/mL) | 95% confidence interval (%) | % Recovery (RSD, n=6) |
|---------------------|---------------------|----------------------------|-----------------------|
| 1.91                | 1.69                | 88.26–91.54                | 90.88 ± 0.81          |
| 3.18                | 2.89                | 90.47–92.84                | 91.42 ± 1.40          |
| 4.56                | 4.21                | 90.54–92.89                | 92.21 ± 0.63          |

### Table 3
| No. | Parameters | Conc. (μg/mL) | RSD (%) | Tailing factor | Resolution | Plate count |
|-----|------------|---------------|---------|----------------|------------|-------------|
| 1.  | Wavelength (nm) | 0.832 | 0.69 | 1.18 | 2.56 | 3532 |
|     | 230        | 0.835 | 0.14 | 1.20 | 2.44 | 3545 |
|     | 232        | 0.832 | 0.11 | 1.20 | 2.56 | 3624 |
|     | 234        | 0.832 | 0.83 | 1.18 | 2.45 | 3580 |
|     | 236        | 0.834 | 1.05 | 1.20 | 2.56 | 3573 |
|     | 238        | 0.832 | 0.11 | 1.20 | 2.56 | 3624 |
| 2.  | Mobile phase composition | 0.832 | 0.34 | 1.23 | 2.46 | 3450 |
|     | 52:33:15   | 0.834 | 0.34 | 1.23 | 2.46 | 3450 |
|     | 53:32:15   | 0.832 | 0.63 | 1.22 | 2.52 | 3521 |
|     | 54:30:16   | 0.832 | 0.92 | 1.18 | 2.52 | 3312 |
|     | 56:30:14   | 0.836 | 0.45 | 1.22 | 2.48 | 3543 |
|     | 57:28:15   | 0.836 | 0.45 | 1.22 | 2.48 | 3543 |
| 3.  | Flow rate (mL/min) | 0.832 | 0.54 | 1.20 | 2.50 | 3455 |
|     | 0.8        | 0.832 | 0.54 | 1.20 | 2.50 | 3455 |
|     | 0.9        | 0.837 | 0.66 | 1.20 | 2.56 | 3461 |
|     | 1.0        | 0.834 | 0.32 | 1.20 | 2.50 | 3578 |
|     | 1.1        | 0.823 | 0.92 | 1.18 | 2.32 | 3343 |
|     | 1.2        | 0.827 | 1.32 | 1.18 | 2.21 | 3211 |

*Mobile phase composition shown as methanol:acetonitrile:water, v/v/v.
3.5. Estimation of NAB in swab samples collected from production lane

Various samples were collected from different sampling points over the production lane. Samples were tested for residual content of NAB. Partial data are shown in Table 4.

4. Conclusion

A validated, selective and simple HPLC-DAD method was developed for residual determination of NAB to demonstrate...
cleaning validation on stainless steel surfaces of the production lane. The method with appropriate swab wipe procedure was found to be precise, accurate and linear. No interference from swab solution was observed and samples were stable for 24 h.

Acknowledgment

Authors are thankful to the IPCA Labs, Ratlam, Madhya Pradesh, India, for analytical standards and gratis samples.

References

[1] Guide to Inspections Validation of Cleaning Processes 7/29, US Food and Drug Administration, (FDA), Office of Regulatory Affairs, Washington, DC, 2011. Cleaning Validation Guidelines (GUIDE-0028) [Health Canada, 2008].pdf (accessed 21.11.2011).
[2] R. Klinkenberg, B. Streel, A. Ceccato, Development and validation of a liquid chromatographic method for the determination of the amlodipine residues on manufacturing equipment surfaces, J. Pharm. Biomed. Anal. 32 (2003) 345–352.
[3] T.T. Fazio, A.K. Singh, E.R.M. Kedor-Hackmann, et al., Quantitative determination and sampling of azathioprine residues for cleaning validation in production area, J. Pharm. Biomed. Anal. 43 (2007) 1495–1498.
[4] T. Mirza, M.J. Lunn, F.J. Keeley, et al., Cleaning level acceptance criteria and a high pressure liquid chromatography procedure for the assay of Meclizine Hydrochloride residue in swabs collected from pharmaceutical manufacturing equipment surfaces, J. Pharm. Biomed. Anal. 19 (1999) 747–756.
[5] K.D. Tripathi, Essential of Medical Pharmacology, fifth ed., Jaypee Brothers Medical Publishers, New Delhi, 2003, pp. 95–496.
[6] Martindale, The Complete Drug Reference, 36th ed., The Pharmaceutical Press, London, 2009, p. 1361.
[7] British Pharmacopoeia, British Pharmacopoeia Commission Office, London, 2004, pp. 1343–1344.
[8] K. Kobylinska, M. Barlinska, M. Kobylinska, Analysis of nabumetone in human plasma by HPLC, application to single dose pharmacokinetic studies, J. Pharm. Biomed. Anal. 32 (2003) 223–228.
[9] M. Nobilis, M. Holcapek, L. Kolaroval, et al., Identification and determination of phase II nabumetone metabolites by high-performance liquid chromatography with photodiode array and mass spectrometric detection, J. Chromatogr. A 1031 (2004) 229–236.
[10] G.M. Chudzik, General guide to recovery studies using swab sampling methods for cleaning validation, J. Validation Technol. 5 (1998) 77–81.
[11] M.J. Schifflet, M. Shapiro, Development of analytical methods to accurately and precisely determine residual active pharmaceutical ingredients and cleaning agents on pharmaceutical surfaces, Am. Pharm. Rev. Winter 4 (2002) 35–39.
[12] M.J. Nozal, J.L. Bernal, J.J. Jimenez, et al., Development and validation of a liquid chromatographic method for determination of lacidipine residues on surfaces in the manufacture of pharmaceuticals, J. Chromatogr. A 1024 (2004) 115–122.
[13] M.J. Nozal, J.L. Bernal, L. Toribio, et al., Development and validation of an LC assay for sumatriptan succinate residues on surfaces in the manufacture of pharmaceuticals, J. Pharm. Biomed. Anal. 30 (2002) 285–291.
[14] B. Boca, Z. Apostolides, E. Pretorius, A validated HPLC method for determining residues of a dual active ingredient anti-malarial drug on manufacturing equipment surfaces, J. Pharm. Biomed. Anal. 37 (2005) 461–468.
[15] A.A. Magda, M.A. Ahmed, A. Ramadan, Validation of an HPLC–UV method for the determination of ceftriaxone sodium residues on stainless steel surface of pharmaceutical manufacturing equipments, J. Pharm. Biomed. Anal. 55 (2011) 247–252.
[16] M.J. Nozal, J.L. Bernal, L. Toribio, et al., Validation of a liquid chromatographic method for the determination of ranitidine hydrochloride residues on surfaces in the manufacture of pharmaceuticals, J. Chromatogr. A 919 (2001) 87–93.
[17] J. Lambropoulos, G.A. Spanos, N.V. Lazaridis, Development and validation of an HPLC assay for fentanyl, alfentanil, and sufentanil in swab samples, J. Pharm. Biomed. Anal. 23 (2000) 421–428.
[18] ICH Harmonised Tripartite Guideline, Q2A, Text on Validation of Analytical Procedures, October 27, 1994.
[19] ICH Harmonised Tripartite Guideline, Impurities in New Drug Products, 3 B(R2), Current Step 4, Version 2, June 2006.
[20] N. Fakutsu, T. Konse, T. Kawasaki, et al., Determination of cefmetazole residue at pharmaceutical manufacturing facilities by chemiluminescence flow injection analysis, J. Pharm. Biomed. Anal. 41 (2006) 599–602.